Cigna SG&A increased by 3.1% to $3.72B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.7%, from $4.21B to $3.72B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
is_selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00B | $3.09B | $3.66B | $3.30B | $3.26B | $3.15B | $3.48B | $3.54B | $3.43B | $3.79B | $4.06B | $3.71B | $3.68B | $3.59B | $3.87B | $4.21B | $3.43B | $3.36B | $3.61B | $3.72B |
| QoQ Change | — | +3.2% | +18.4% | -9.9% | -1.3% | -3.3% | +10.6% | +1.6% | -2.9% | +10.3% | +7.2% | -8.8% | -0.6% | -2.6% | +7.7% | +9.0% | -18.5% | -2.1% | +7.3% | +3.1% |
| YoY Change | — | — | — | — | +8.7% | +1.8% | -4.9% | +7.2% | +5.5% | +20.3% | +16.6% | +4.7% | +7.3% | -5.2% | -4.8% | +13.7% | -6.8% | -6.4% | -6.6% | -11.7% |